ArticleRSC advances2026
Development of an AQbD-guided sustainable RP-HPLC method for simultaneous quantification of saracatinib and rapamycin in lipid-polymer hybrid nanocarriers.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Saracatinib (SRC) and Rapamycin (RAP) are promising targeted anticancer agents that act through dual Src/Abl kinase inhibition and mTOR pathway suppression, respectively, demonstrating synergistic efficacy in head and neck cancer models. To overcome limitations such as poor tumor selectivity, low solubility, and systemic toxicity, both drugs were co-encapsulated into lipid-polymer hybrid nanoparticles (LPHNPs) to enhance bioavailability and therapeutic performance. However, no validated analytical approach has been reported for their simultaneous quantification in such nanocarrier systems. This research presents the development and optimization of a robust, sustainable and green reverse-phase high-performance liquid chromatography (RP-HPLC) method using an Analytical Quality by Design (AQbD) strategy. A Box-Behnken design was utilized to systematically evaluate critical method parameters (CMPs) and establish a design space, ascertaining consistent performance. Chromatographic separation was achieved under optimized isocratic RP-HPLC conditions with baseline resolution of both analytes. SRC and RAP were eluted at 3.787 and 9.462 minutes, respectively. The validated method showed outstanding linearity over the studied concentration, with an
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.